KSQ Therapeutics Stock
Drug discovery company
Sign up today and learn more about KSQ Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About KSQ Therapeutics Stock
KSQ Therapeutics states that it is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by a proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a more comprehensive understanding of disease biology. The quality of these insights enables their scientists to identify and validate high-confidence, patient-tailored drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Funding History
October 2017 | $76.0M |
---|---|
September 2018 | $80.0M |
Management
CSO
Frank Stegmeier
Founder
David Sabatini
VP, Head of Chemistry and Drug Design
René M. Lemieux
Sr. Director, Head of Corporate Development
John Trzupek
Managing Director & CEO
David Meeker
Press
patents - Apr, 14 2024
Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of …patents - Apr, 14 2024
Gene-regulating compositions and methods for improved immunotherapypatents - Apr, 14 2024
Gene-regulating compositions and methods for improved immunotherapypatents - Apr, 14 2024
Therapeutic combinations comprising ubiquitin- specific-processing protease 1 ( …patents - Apr, 14 2024
Solid state forms of substituted pyrazolopyrimidines and uses thereof